Newbridge Financial Services Group’s GoodRx Holdings GDRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$15K Sell
5,192
-14
-0.3% -$36 ﹤0.01% 775
2026
Q1
$10.2K Sell
5,206
-182
-3% -$427 ﹤0.01% 790
2025
Q4
$14.6K Buy
5,388
+388
+8% +$1.27K ﹤0.01% 715
2025
Q3
$21.1K Hold
5,000
﹤0.01% 730
2025
Q2
$24.9K Hold
5,000
﹤0.01% 666
2025
Q1
$22.1K Hold
5,000
0.01% 526
2024
Q4
$23.3K Hold
5,000
0.01% 564
2024
Q3
$34.7K Hold
5,000
0.01% 305
2024
Q2
$39K Hold
5,000
0.01% 423
2024
Q1
$35.5K Hold
5,000
0.02% 471
2023
Q4
$33.5K Hold
5,000
0.02% 486
2023
Q3
$28.1K Hold
5,000
0.01% 564
2023
Q2
$27.6K Hold
5,000
0.01% 599
2023
Q1
$31.3K Hold
5,000
0.02% 583
2022
Q4
$23.3K Hold
5,000
0.01% 669
2022
Q3
$23K Buy
+5,000
New +$31.5K 0.01% 652

Other funds holding GDRX

Newbridge Financial Services Group's GDRX Position: Q2 2026 in Review

Newbridge Financial Services Group reduced its GoodRx Holdings (GDRX) stake by 0.27% in Q2 2026, selling an estimated $36 and leaving 5,192 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #775.

Newbridge Financial Services Group first reported a position in GDRX in Q3 2022 and has held it in 16 quarters since. The position peaked at $39K in Q2 2024. 162 funds tracked by Wall St. Rank hold GDRX as of Q2 2026.

  • Newbridge Financial Services Group held 5,192 shares of GoodRx Holdings worth $15K as of Q2 2026.
  • Newbridge Financial Services Group sold 14 GoodRx Holdings shares in Q2 2026, an estimated $36.
  • GoodRx Holdings made up ﹤0.01% of Newbridge Financial Services Group's portfolio in Q2 2026, its #775 holding.
  • Newbridge Financial Services Group first reported a position in GoodRx Holdings in Q3 2022 and has held it in 16 quarters since.
  • Newbridge Financial Services Group's GoodRx Holdings position peaked at $39K in Q2 2024.
  • 162 funds tracked by Wall St. Rank held GoodRx Holdings as of Q2 2026.

Based on Newbridge Financial Services Group's 13F filing for Q2 2026, filed 14 Aug 2026.